Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 318

1.

Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants.

Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, Kieninger D, Siegrist CA, Zepp F.

J Pediatr. 2008 May;152(5):655-60, 660.e1. doi: 10.1016/j.jpeds.2007.09.034. Epub 2007 Nov 19.

PMID:
18410769
2.

Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age.

Wood N, McIntyre P, Marshall H, Roberton D.

Pediatr Infect Dis J. 2010 Mar;29(3):209-15. doi: 10.1097/INF.0b013e3181bc98d5.

PMID:
20009964
3.

Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.

Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L; Spanish DTaP-HBV-IPV-097 Study Group.

Pediatr Infect Dis J. 2006 Aug;25(8):713-20.

PMID:
16874171
6.
8.

Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.

Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton PM, Panzer F, Rose T, Koller DY, Van Damme P, Schödel F.

Pediatr Infect Dis J. 2009 Mar;28(3):177-81. doi: 10.1097/INF.0b013e31818c0161.

PMID:
19209092
9.
10.

Booster vaccination after neonatal priming with acellular pertussis vaccine.

Knuf M, Schmitt HJ, Jacquet JM, Collard A, Kieninger D, Meyer CU, Siegrist CA, Zepp F.

J Pediatr. 2010 Apr;156(4):675-8. doi: 10.1016/j.jpeds.2009.12.019.

PMID:
20303444
11.
12.
13.

Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.

Halperin SA, Tapiero B, Law B, Diaz-Mitoma F, Duval B, Langley JM, Elrick DB, Jacquet JM.

Vaccine. 2006 May 1;24(18):4017-23. Epub 2005 Nov 21.

PMID:
16516357
15.

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.

Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.

Vaccine. 2006 Jul 7;24(27-28):5627-36. Epub 2006 May 2.

PMID:
16740348
16.

Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.

Omeñaca F, Garcia-Sicilia J, Boceta R, Sistiaga-Hernando A, García-Corbeira P.

Pediatr Infect Dis J. 2007 Sep;26(9):824-9.

PMID:
17721379
17.
18.

Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.

Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.

Southeast Asian J Trop Med Public Health. 2009 Mar;40(2):282-94.

PMID:
19323013
20.

Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.

Wood N, Nolan T, Marshall H, Richmond P, Gibbs E, Perrett K, McIntyre P.

JAMA Pediatr. 2018 Nov 1;172(11):1045-1052. doi: 10.1001/jamapediatrics.2018.2349.

Supplemental Content

Support Center